RIBOZYME AND OMICS

고객지원

News

Rznomics Passed Technology Evaluation, Advancing Toward KOSDAQ Listing

  • 작성자
    관리자
  • 날짜
    2025-06-11
- Received “A, A” ratings from two technology evaluation institutions designated by the Korea Exchange
- Plans to submit preliminary review application for KOSDAQ listing in the second half of the year


Rznomics, a developer of RNA-based gene therapies, announced on June 11 that it has passed the technology evaluation required for a technology-special listing on the KOSDAQ market.

The company received “A” grades from two technology evaluation institutions designated by the Korea Exchange (KRX), recognizing both its technological excellence and business potential. Rznomics plans to leverage the Deep Tech Track of the technology-special listing system starting in the second half of the year, with the goal of completing its KOSDAQ listing in the first half of next year.

The technology evaluation is a mandatory step for the technology-special listing and assesses technological maturity, competitiveness, commercialization potential, and marketability. Under the Deep Tech Track—a newly introduced fast-track system—companies based on advanced science and national strategic technologies can apply for preliminary listing review with a single technology evaluation.

In May 2024, Rznomics was recognized as the "National Strategic Technology Company No. 1" by the Ministry of Science and ICT (MSIT) and the Korea Institute of Science and Technology Planning and Evaluation (KISTEP). Later in September, the company was designated as a "National Strategic Technology Possession and Management Company," thereby qualifying for the Deep Tech Track. If successfully listed through this route, Rznomics would become the first company designated under MSIT’s national strategic technology program to achieve listing via the deep tech special track.

Founded in 2017, Rznomics is developing anti-cancer and rare disease therapies using its proprietary RNA editing and correction platform based on RNA replacement enzymes. Founder and CEO Dr. Seong-Wook Lee began his RNA replacement enzyme research at Duke University Medical Center in the U.S., and has continued this work for over 20 years as a professor at Dankook University since 1997.

Currently, the company is conducting Phase 1b/2 and Phase 1/2a clinical trials in South Korea and the United States for “RZ-001,” a gene therapy targeting hepatocellular carcinoma (HCC) and glioblastoma. Both indications have received Orphan Drug Designation (ODD) and Fast Track designation from the U.S. Food and Drug Administration (FDA). For glioblastoma, the therapy is also being provided to patients under an Expanded Access Program (EAP) due to the lack of alternative treatments. In addition, “RZ-004,” a therapy for hereditary retinitis pigmentosa, has received approval for a Phase 1 trial in Australia, with patient enrollment expected to begin soon.

In May, Rznomics signed a strategic global licensing agreement with U.S. pharmaceutical company Eli Lilly and Company to co-develop RNA editing therapies, further validating the global competitiveness and commercial potential of its platform technology. The company is also expanding its scope beyond RNA replacement enzymes to include circular RNA platforms and is collaborating with various companies on vaccine and therapeutic development and validation.

Despite a challenging biotech investment environment in the second half of last year, Rznomics successfully raised KRW 20.3 billion (around USD 15M) in a Pre-IPO Series round from investors including KB Investment, Aon Investment, Yuanta Investment, Samsung Venture Investment, and Quad Ventures, demonstrating its strong market potential.

CEO Dr. Seong-Wook Lee commented, “Passing the technology evaluation marks official recognition of Rznomics’ proprietary RNA-based platform and its growth potential,” adding, “Through our KOSDAQ listing, we aim to establish a solid foundation for business expansion and become a global leader in RNA editing.”

PREV
Rznomics Enters Global Licensing Agreement with Eli Lilly for RNA-editing Therap...
LIST
LIST
NEXT
No Next Data.